Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes  : Episode 3

Strategies to Managing Cardiotoxic AEs with Osimertinib

January 29, 2025

Opinion

Video

Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy.

EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC

EP: 2.Patient Guidance and Education of EGFR Inhibitor Therapies

Now Viewing

EP: 3.Strategies to Managing Cardiotoxic AEs with Osimertinib

EP: 4.Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

EP: 5.Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors

EP: 6.Management of GI Toxicities in Osimertinib and other EGFR Inhibitors

EP: 7.Importance of Multidisciplinary Team in Managing AEs of EGFR Inhibitors

EP: 8.Comparison of Safety Profiles of EGFR Inhibitors

EP: 9.Jason’s Journey with ALK+ Metatstatic NSCLC

EP: 10.Patient Education and Guidance on Lorlatinib and Other ALK Inhibitors

EP: 11.Management of Neurotox AEs with Lorlatinib

EP: 12.Management of Hyperlipidemia and Weight Gain with Lorlatinib

EP: 13.Management of GI AEs with ALK Inhibitors

EP: 14.Dose Modifications When Managing Side Effects with ALK Inhibitors

EP: 15.Role of Multidisciplinary Strategies in care of ALK+ NSCLC Patients

EP: 16.Patient Factors in Treatment Selection of ALK Inhibitors

Video content above is prompted by the following:

What strategies do you use for managing cardiotoxicity in patients on osimertinib?
How do you monitor these adverse events and balance symptom management with maintaining treatment efficacy?

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!